Selective antagonism of SSTR2 has been shown in various non-clinical models of T1D and in early phase clinical trials to at least partially restore glucagon counterregulation, with the goal of reducing hypoglycemia exposure in insulin-requiring diabetes. Here, INS is linked to diabetes mellitus.